10 terminated. 10 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Terminated 10 |
| Phase 2 | 4 | Terminated 4 |
Follow Myeloma: new trials by email Literature Review of Myeloma trials Research Report on Myeloma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| FT538 in Subjects With Advanced Hematologic Malignancies FT538, Cyclophosphamide, Fludarabine - Acute Myeloid Leukemia, AML, Adult | Phase 1 | Terminated | Fate Therapeutics | 42 | 2020-10-17 | 2023-09-21 |
| Positron Emission Tomography (PET) Imaging Studies With NIS Reporter BF4 - Myeloma, Endometrial Cancer | Phase 1 / Phase 2 | Terminated | Mayo Clinic | 8 | 2016-09-01 | 2019-05-17 |
| Ascending Dose and Exploratory Expansion Study of DS-3032b, an Oral MDM2 Inhibitor, in Subjects With Relapsed and/or Refractory Multiple Myeloma DS-3032b - Myeloma | Phase 1 | Terminated | M.D. Anderson Cancer Center | 14 | 2016-08-30 | 2019-11-15 |
| Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis Pomalidomide, Melphalan, Dexamethasone - Myeloma | Phase 1 | Terminated | M.D. Anderson Cancer Center | 3 | 2014-01-01 | 2016-05-13 |
| Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene Fludarabine, Melphalan, Alemtuzumab - Leukemia, Myeloma | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 3 | 2013-12-27 | 2019-07-16 |
| Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple Myeloma Lenalidomide, Dexamethasone, All-Trans Retinoic Acid (ATRA) - Myeloma | Phase 1 | Terminated | M.D. Anderson Cancer Center | 2 | 2013-12-01 | 2016-09-14 |
| Clinical Ex Vivo Expansion of Human Umbilical Cord Blood Stem and Progenitor Cells Ex vivo expanded cord blood cells - Acute Leukemia, Chronic Leukemia | Phase 1 / Phase 2 | Terminated | Singapore General Hospital | 3 | 2012-03-01 | 2015-11-30 |
| Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps Fludarabine, Thiotepa, Total Body Irradiation (TBI) - Hematologic Malignancies, Acute Leukemia | Phase 1 / Phase 2 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 8 | 2011-04-01 | 2025-05-31 |
| Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid Malignancies Rituximab, Cyclophosphamide, Fludarabine - Leukemia, Lymphoma | Phase 1 | Terminated | M.D. Anderson Cancer Center | 4 | 2007-05-01 | 2011-12-19 |
| Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies Fludarabine, Melphalan, Campath - Preleukemia, Myeloproliferative Disorders | Phase 1 | Terminated | University of Chicago | 1 | 2003-05-01 | 2014-03-17 |
Neoplasms, Plasma Cell (10) · Lymphoma (4) · Multiple Myeloma (4) · Leukemia (3) · Myelodysplastic Syndromes (3) · Graft vs Host Disease (2) · Hodgkin Disease (2) · Amyloidosis (1) · Endometrial Neoplasms (1) · Hematologic Neoplasms (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myeloid, Acute (1) · Lymphoma, Non-Hodgkin (1) · Myeloproliferative Disorders (1) · Preleukemia (1)
Neoplasms (10) · Neoplasms by Histologic Type (10) · Hematologic Diseases (8) · Hemic and Lymphatic Diseases (8) · Immune System Diseases (8) · Immunoproliferative Disorders (8) · Lymphoproliferative Disorders (8) · Lymphatic Diseases (5) · Blood Protein Disorders (4) · Bone Marrow Diseases (4) · Cardiovascular Diseases (4) · Hemorrhagic Disorders (4) · Hemostatic Disorders (4) · Paraproteinemias (4) · Vascular Diseases (4)
fludarabine (5) · Melphalan (4) · fludarabine phosphate (3) · Alemtuzumab (2) · Calcium Dobesilate (2) · Cyclophosphamide (2) · Dexamethasone (2) · Radiotherapy (2) · Surveys and Questionnaires (2) · AP 1903 reagent (1) · Filgrastim (1) · Granulocyte Colony-Stimulating Factor (1) · Hematopoietic Stem Cell Transplantation (1) · Lenalidomide (1) · Lymphocyte Count (1)
M.D. Anderson Cancer Center (5) · Fate Therapeutics (1) · Mayo Clinic (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1) · Singapore General Hospital (1) · University of Chicago (1)
United States (9) · Singapore (1)
Andrew Artz, M.D. (1) · Dolores Grosso, DNP, CRNP (1) · Hans C. Lee, MD (1) · Jatin J. Shah, MD (1) · Neal Flomenberg, MD (1) · Richard E. Champlin, MD (1) · Richard E. Champlin, MD, BS (1) · Robert Orlowski, MD, PHD (1) · Timothy R DeGrado (1) · William YK Hwang, MBBS, FRCP (1)